Alpha emitter radium-223 and survival in metastatic prostate cancer.

By C. Parker, Sten Nilsson, D. Heinrich, S. Helle, J. O’Sullivan, S. Fosså, Aleš Chodacki, P. Wiechno, John P. Logue, Mihalj Seke and 20 more. New England Journal of Medicine, 2013

3,066 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/5f76f57891cfbaafe43736fad66565f2decabdf4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. M. Hallek
2. Michel Bolla
3. N. Mottet
4. J. Bellmunt
5. Steven Joniau
6. Thomas Wiegel

Citations in the corpus

• Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. (2017, background): “Although significant treatment advances have been made recently with the introduction of novel therapeutic agents, such as enzalutamide, abiraterone acetate, cabazitaxel, and radium 223, prognosis and long-term outcomes for patients with castration-resistant prostate cancer (CRPC) need to be improve”
• German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients (2017, background): “Patients undergoing placebo or 223Ra within the ALSYMPCA trial (21) demonstrated grade $ 3 anemia in 13%–14% and grade $ 3 thrombocytopenia in 3%–7%.”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “88) Improved 5 [100]”
• EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017, background): “The associated toxicity was mild and, apart from slightly more haematologic toxicity and diarrhoea with Ra 223, did not differ significantly from that in the placebo arm [83].”
• Prostate Cancer (2018, background): “Their results demonstrated approximately a 20% reduction in prostate cancer mortality in those who underwent annual PSA screening [6, 14, 15].”
• Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy (2017, neutral): “of patients reporting treatment after progression) 248 248 248 248 Any Docetaxel Abiraterone Enzalutamide (168) (83) (3) (5) 51 110 179 179 (21) (25) (3) (10) 21 58 122 116 (6) (5) (2) (8) 2 13 32 25 (1) (1) (0) (2) 18”
• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. (2020, background): “The results of the Prostate Testing for Cancer and Treatment (ProtecT) trial (n = 1643 men) reported no difference in the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30–assessed global QoL, up to 5 yr of follow-up, in 50–69-yr-old men with T1-T2 disease randomised for tre”